Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,003,252 papers from all fields of science
Search
Sign In
Create Free Account
Bortezomib-Dexamethasone Regimen
Known as:
Velcade-Dexamethasone Regimen
A regimen consisting of bortezomib and dexamethasone used as treatment for relapsed or refractory multiple myeloma.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Dexamethasone
Multiple Myeloma
bortezomib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Nonamyloidotic Light Chain Cardiomyopathy: The Arrhythmogenic Magnetic Resonance Pattern.
M. De Lazzari
,
M. Fedrigo
,
+10 authors
M. Perazzolo Marra
Circulation
2016
Corpus ID: 207604362
Light chain deposition disease (LCDD) is a rare plasma cell dyscrasia consisting of nonamyloidotic deposition of misfolded…
Expand
2013
2013
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma
W. Pönisch
,
Malvina Bourgeois
,
+19 authors
D. Niederwieser
Journal of Cancer Research and Clinical Oncology
2013
Corpus ID: 23752965
IntroductionBortezomib (Velcade®) is a proteasome inhibitor that has shown important clinical efficacy either as a single agent…
Expand
2013
2013
Mr-016. Phase Ii Pilot Study Of Velcade® (bortezomib) In Combination With Temozolomide And Regional Radiation Therapy For Upfront Treatment Of Patients With Newly-diagnosed Glioblastoma Multiforme
X. Kong
,
S. Green
,
+5 authors
A. Lai
2013
Corpus ID: 81057092
PURPOSE: To assess interim safety and tolerability of 12 patients in a phase II pilot study using Bortezomib in combination with…
Expand
2012
2012
A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma
A. Beaven
,
T. Shea
,
+6 authors
A. Goy
Leukemia and Lymphoma
2012
Corpus ID: 1108632
Abstract Proteasome inhibitors may inhibit DNA repair of radiation-induced strand breaks and adducts thereby making the…
Expand
2009
2009
Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines
J. Wagenblast
,
M. Baghi
,
+6 authors
R. Knecht
Journal of Cancer Research and Clinical Oncology
2009
Corpus ID: 10477662
PurposeProteasome inhibition has been shown to be effective in multiple myeloma and solid tumor models. In this in vitro study…
Expand
2008
2008
Phase I Results of Combination Gemcitabine and Bortezomib (Velcade®) for Relapsed/Refractory Nodal T-Cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL).
A. Evens
,
L. Gordon
,
+5 authors
Sonali M. Smith
2008
Corpus ID: 78238289
NF-κB is deregulated in several lymphoma subtypes, including aggressive B-NHL and T-NHL. The proteasome inhibitor, bortezomib…
Expand
2007
2007
Antitumor activity of Aplidin® in combination with Velcade® (bortezomib) in human multiple myeloma.
Halina Sasak
,
D. Lepage
,
+5 authors
G. Faircloth
2007
Corpus ID: 201981269
4762 Aplidin ® (plitidepsin) is a novel anticancer drug, isolated from the marine tunicate Aplidium albicans, showing potent…
Expand
2007
2007
Charakterisierung der potentiellen Lebertoxizität und tumorspezifischen Apoptoseinduktion durch eine kombinierte TRAIL/Bortezomib-Behandlung gastrointestinaler Tumore
R. Koschny
,
J. Sykora
,
+5 authors
T. Ganten
2007
Corpus ID: 58753392
Als Mitglied der TNF-Superfamilie induziert TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand) Apoptose in…
Expand
2006
2006
Phase II Study of Proteasome Inhibitor Bortezomib (Velcade®) in Patients with Relapsed/Refractory T-Cell Lymphoma: Preliminary Results.
P. Zinzani
,
M. Tani
,
+4 authors
M. Baccarani
2006
Corpus ID: 78562066
The mechanisms by which Bortezomib elicits its antitumor activity may vary among tumor types, and the extent to which each…
Expand
2006
2006
Safety and Efficacy of Bortezomib (VELCADE™) in 104 Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy: Impact of Cytogenetics on…
J. Mikhael
,
D. Reece
,
A. Belch
,
N. Bahlis
,
Deepanshu Sharma
2006
Corpus ID: 57250044
Background: Bortezomib (VELCADE™) is a reversible proteasome inhibitor that has been shown to be safe and efficacious in patients…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE